|
KMID : 1030220130140030125
|
|
Journal of Korean Diabetes
2013 Volume.14 No. 3 p.125 ~ p.127
|
|
|
Clinical Efficacy of Glucagon Like Peptide-1 (GLP-1) Analogues
|
|
Chun Hyun-Ji
Kwon Hyuk-Sang
|
|
|
Abstract
|
|
|
|
Recently, incretin hormone-based therapies, including glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors, have become the main therapeutic tools in the hyperglycemia management in patients with type 2 diabetes mellitus. These therapeutic agents could fill an important gap in glycemic control for patients with type 2 diabetes because the incretin response is blunted in type 2 diabetes mellitus. GLP-1 analogues can be classified as exendin-4 backbone (Exenatide, Exenatide LAR and Lixisenatide) and human GLP-1 backbone (Liraglutide, Taspoglutide and Albiglutide). Among these, Exenatide, Exenatide LAR and Liraglutide are currently available. This review will focus on the clinical efficacies of GLP-1 analogues in glycemic control for patients with diabetes.
|
|
|
KEYWORD
|
|
|
Type 2 diabetes mellitus, GLP-1 analogues, Incretins
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|